FibroBiologics to Present Corporate Update at 2023 BIO International Convention

Clinical-Stage Company Focused on Advancing Fibroblast Cell-Based Therapies for Treatment of Chronic Diseases HOUSTON, June 1, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced that Pete O’Heeron, Founder and Chief Executive Officer, will present a corporate overview next week at the 2023 BIO International […]

FibroBiologics has released its annual report Form C-AR

FibroBiologics has released its annual report Form C-AR for the year ended December 31, 2022 – FibroBiologics is a clinical-stage cell therapy company focused on developing and commercializing fibroblast cell-based and fibroblast cell-derived product candidates as therapeutics for patients suffering from chronic diseases with significant unmet medical needs.